Guizhounli Pharmaceutical Co (SHSE:603439) ROCE %: 12.24% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603439 Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
90 GF Score
Price ¥11.41
GF Value ¥14.70
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Guizhounli Pharmaceutical Co ROCE %?

Guizhounli Pharmaceutical Co SHSE:603439 -1.98% 90 ROCE % is 12.24% as of Mar. 2026. GuruFocus rates SHSE:603439 with a GF Score™ of 90/100 and a GF Value™ of ¥14.70 (Modestly Undervalued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Guizhounli Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.24%.

Guizhounli Pharmaceutical Co  (SHSE:603439) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Guizhounli Pharmaceutical Co ROCE % Related Terms

Guizhounli Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Guizhounli Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhounli Pharmaceutical Co ROCE % Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.14 19.70 20.19 16.82 4.18

Guizhounli Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.31 10.11 -0.05 -4.55 12.24
SHSE:603439
90GF Score
Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guizhounli Pharmaceutical Co ROCE % Calculation

Guizhounli Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=78.84/( ( (3192.108 - 1234.457) + (2847.923 - 1037.171) )/ 2 )
=78.84/( (1957.651+1810.752)/ 2 )
=78.84/1884.2015
=4.18 %

Guizhounli Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=224.412/( ( (2847.923 - 1037.171) + (2810.723 - 953.888) )/ 2 )
=224.412/( ( 1810.752 + 1856.835 )/ 2 )
=224.412/1833.7935
=12.24 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.24% mean?
Guizhounli Pharmaceutical Co (SHSE:603439) has a ROCE % of 12.24% as of Mar. 2026.
Is Guizhounli Pharmaceutical Co's ROCE % too high?
Guizhounli Pharmaceutical Co's current ROCE % is 12.24%. The Drug Manufacturers industry median ROCE % is 7.04. Guizhounli Pharmaceutical Co's value of 12.24% is 73.9% above this industry median. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's ROCE % compare to ZTS and UTHR?
Guizhounli Pharmaceutical Co's ROCE % of 12.24% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Guizhounli Pharmaceutical Co's value of 12.24% is 73.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current ROCE % of 12.24% is 73.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current ROCE % is 12.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.70, compared to a current price of ¥11.41 — trading 22.4% below its estimated fair value. The current ROCE % is 12.24% and 73.9% above the Drug Manufacturers industry median of 7.04. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current ROCE % is 12.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥11.41 is trading 22.4% below its estimated GF Value™ of ¥14.70. GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603439:

  • ROCE %: 12.24%
  • GF Value™: ¥14.70 vs. price of ¥11.41 (22.4% below fair value)
  • GF Score™: 90/100 with 10 warning signs
  • Industry Position: 73.9% above the Drug Manufacturers median

No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guizhounli Pharmaceutical Co Business Description

Address Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score

Get the complete analysis for SHSE:603439

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.41
Price
¥14.70
GF Value